“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Dr. Scott Forrest is currently the Chief Business Officer of Shoreline Therapeutics. Prior to joining Shoreline, he was Chief Financial Officer of Autobahn Therapeutics, where he was responsible for corporate development, portfolio planning, and financial strategy. Prior to Autobahn, Dr. Forrest served as Chief Operating Officer and Chief Financial Officer at Inception Therapeutics, a Versant Ventures discovery engine focused on building and operating transformative biotech companies.
In this role, he played an integral leadership role in multiple companies, including Lycia Therapeutics, Contineum (prev. Pipeline Therapeutics), and Chinook Therapeutics. Prior to Inception, Dr. Forrest was a Co-Founder and Vice President of Operations and Corporate Development at Neumora (prev. BlackThorn Therapeutics). Earlier, he was Vice President of Business Development at The Scripps Research Institute, where he oversaw the creation and launch of more than 15 new biotech companies and led the negotiation and management of over $200 million in corporate alliances. He also held director or board observer positions with several companies, including Zyngenia, Abide, Padlock, and Epic Sciences.
Dr. Forrest started his career at the University of North Carolina, where he led the restructuring, expansion, and management of the life sciences licensing team. He also served as an entrepreneur in residence at UNC and was a central part of the successful launch of multiple startup companies such as Epizyme. Dr. Forrest holds a B.S. in biochemistry from the University of Calgary and a Ph.D. in pharmacology from the University of Virginia.
